Drug Profile
Esketamine - Celon Pharma
Alternative Names: Esketamine DPI; Falkieri; PG061; S-ketamine - CelonLatest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator Celon Pharma
- Developer Celon Pharma; The National Centre for Research and Development
- Class Analgesics; Antidepressants; Chlorobenzenes; Cyclohexanones; General anaesthetics; Small molecules
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bipolar depression; Depressive disorders
Most Recent Events
- 22 Sep 2023 No development reported - Phase-II for Bipolar depression (Adjunctive treatment, Treatment-resistant) in Poland (Inhalation)
- 22 Sep 2023 No development reported - Phase-II for Depressive disorders (Treatment-resistant) in Poland (Inhalation)
- 09 Jul 2021 Celon Pharma plans phase III trials for Bipolar depression (Inhalation, Powder) in second half of 2021